Late-breaking poster presentations (as of 9/20/23)

Poster Session C  
Saturday, October 14 | 12:30 pm-4:00 pm  
Level 2, Exhibit Hall D

LB_C02: A phase 1b dose escalation study of AV-380 in combination with standard of care chemotherapy in metastatic cancer patients (pts) with cachexia and elevated GDF-15 levels. Martin Birkhofer, AVEO Oncology, Boston, MA United States.

LB_C03: Protein translation inhibition enforces histone deacetylase inhibitor activity resulting in synergistic pancreatic cancer cell death. Maryam Safari, Columbia University Medical Center, New York, NY United States.


LB_C07: Utilizing a BCL-2 inhibitor (venetoclax) to overcome doxorubicin resistance in triple-negative breast cancer. Evan Dus, University of Colorado Anschutz, Aurora, CO United States.

LB_C09: QTX3034, a potent and selective multi-KRAS inhibitor, synergizes with EGFR inhibitors and enhances anti-tumor activity. Jillian M. Silva, Quanta Therapeutics, South San Francisco, CA United States.


LB_C12: Alisertib and pembrolizumab in Rb-deficient head and neck squamous cell carcinomas (HNSCC). Faye M. Johnson, University of Texas MD Anderson Cancer Center, Houston, TX United States.


LB_C15: *PI3Kδ/γ inhibitor as a novel immune-regulatory radiosensitizer*. Jae-Sung Kim, Korea Institute of Radiological & Medical Sciences, Nowon-gu, Korea, Republic of.

LB_C16: *Long-read sequencing reveals alternative splicing driven, shared immunogenic neoepitopes regardless SF3B1 status in uveal melanoma*. Jianfeng Shen, Shanghai Jiao Tong University School of Medicine, Shanghai, China (Mainland).

LB_C17: *Spatial Tumor Immune Microenvironment Analysis of KRAS-mutated Non-Small Cell Lung Cancer and Immunotherapy Outcome*. Dan Zhao, MD Anderson Cancer Center, Houston, TX United States.


LB_C20: *A tumor-associated chemokine attracts CCR4-expressing CD4+ cells to foster immune repression and tumor aggressiveness in MYCN-driven neuroblastoma*. Xiaodan Qin, Boston University Chobanian & Avedisian School of Medicine, Boston, MA United States.

LB_C21: *Exogenous N-acetylgalactosamine-4-sulfatase(ARSB)-mediated tumor suppression involves effects on chondroitin 4-sulfate binding with SHP-2 and galectin-3, MAPK signaling, and transcriptional events, including epigenetic regulation of P*. Joanne K. Tobacman, University of Illinois Chicago and Jesse Brown VA Medical Center, Chicago, IL United States.